menu search

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectively Phase 1 clinical trial in healthy subjects initiated in New Zealand Phase 2 proof-of-concept clinical trial of batoclimab in Graves’ disease (GD) initiated in Germany Global clinical trials of batoclimab are ongoing in myasthenia gravis (MG), […] The post Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Yea... Read More
Posted: May 22 2023, 11:00
Author Name: forextv
Views: 112575

Search within

Pages Search Results: